A community effort in SARS-CoV-2 drug discovery

Area of Science:

• Drug Discovery
• Computational Chemistry
• Virology

Background:

• The COVID-19 pandemic necessitates continuous development of accessible small-molecule therapeutics.
• Vaccines alone are insufficient, highlighting the need for diverse treatment options, especially in resource-limited settings.

Purpose of the Study:

• To identify novel small-molecule inhibitors against SARS-CoV-2 targets using an open science, crowdsourced computational screening approach.
• To leverage a large-scale virtual screening effort involving a global community to accelerate drug discovery.

Main Methods:

• The
• Billion Molecules against COVID-19 challenge
• involved 31 teams computationally screening over 1 billion virtual molecules against 6 key SARS-CoV-2 protein targets.
• A consensus ranking identified promising compounds, followed by experimental synthesis and biological testing of 878 selected molecules.
• Assays included binding, cleavage inhibition, and viral suppression to evaluate compound efficacy.

Main Results:

• 27 compounds demonstrated weak inhibition or binding against SARS-CoV-2 targets, including proteases, nucleocapsid protein, and spike protein.
• The study identified potential lead compounds for further optimization in COVID-19 drug discovery.
• This large-scale collaborative effort showcased the power of open science in tackling global health challenges.

Conclusions:

• Open science initiatives can significantly contribute to identifying potential therapeutic agents for viral diseases like COVID-19.
• The identified compounds provide a starting point for developing more potent and widely accessible SARS-CoV-2 treatments.
• This approach enhances the collective knowledge base for future infectious disease drug discovery efforts.